Kiniksa Pharmaceuticals International, plc reported significant financial performance improvements in its latest quarterly filing, with total revenue reaching $180.9 million for the three months ended September 30, 2025, compared to $112.2 million for the same period in 2024. This represents a 61.2% increase, primarily driven by higher sales of its product ARCALYST, which generated $180.9 million in product revenue, up from $112.2 million year-over-year. For the nine months ending September 30, 2025, total revenue was $475.4 million, a substantial increase from $294.5 million in the prior year. The company reported a net income of $18.4 million for the third quarter, a turnaround from a net loss of $12.7 million in the same quarter last year, and a net income of $44.8 million for the nine-month period, compared to a loss of $34.3 million in 2024.
The company’s operating expenses also increased, totaling $156.8 million for the third quarter, up from $121.9 million in the previous year. This rise was attributed to higher collaboration expenses, which surged to $63.3 million from $29.3 million, reflecting the profit-sharing agreement with Regeneron related to ARCALYST sales. Research and development expenses decreased slightly to $24.2 million from $26.1 million, while selling, general, and administrative expenses rose to $49.1 million from $46.4 million, largely due to increased personnel costs.
Kiniksa has made strategic advancements, including the ongoing technology transfer of ARCALYST drug substance manufacturing to Samsung Biologics, which is expected to enhance production capabilities. The company is also actively pursuing clinical trials for its product candidates, including KPL-387, which is currently in a Phase 2/3 trial for recurrent pericarditis. The company’s employee headcount has increased, reflecting its expansion efforts to support commercialization and development activities.
As of September 30, 2025, Kiniksa reported cash, cash equivalents, and short-term investments totaling $352.1 million, which the company believes will be sufficient to fund its operations for at least the next 12 months. The company has committed to significant future payments under various agreements, including $204.9 million in minimum purchase commitments related to its supply agreements and other operational costs. Kiniksa's outlook remains focused on the continued commercialization of ARCALYST and advancing its pipeline of product candidates, with expectations of further revenue growth driven by increased patient enrollment and market expansion.
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals develops and commercializes biologic therapies targeting inflammatory and autoimmune diseases, primarily focusing on cardiovascular conditions like recurrent pericarditis. Its portfolio includes ARCALYST, an IL-1 cytokine trap, and investigational monoclonal antibodies such as KPL-387 and KPL-1161. The company partners globally, leveraging licensing, out-licensing, and strategic collaborations to advance innovative treatments for unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.